User Avatar

Charlie Lees

3y ago

3 hot off the press pharma stories about new molecules for IBD

• upadacitinib gains MHRA approval for Crohn's disease

• filgotinib fails to meet key Crohn's endpoints in DIVERSITY

• Takeda complete deal with Nimbus to acquire promising TYK2 molecule

Links below in 🧵

1/5

User Avatar

Charlie Lees

3y ago

Upadacitinib (Rinvoq - Abbvie) receives its first global licence for Crohn's disease

MHRA grants approval for use in the UK

NICE and SMC approvals should follow soon in the UK

https://news.cision.com/abbvie/r/mhra-approves-rinvoq---upadacitinib--as-first-oral-advanced-therapy-to-treat-adults-with-moderately-,c3707330

2/5

User Avatar

Charlie Lees

3y ago

DIVERSITY enrolled 1374 patients with Crohn's disease

The press release notes that not all key primary outcomes were met

Galapagos decides not to pursue filgotinib for this indication

Does not affect use in UC

https://firstwordpharma.com/story/5704387

3/5

User Avatar

Charlie Lees

3y ago

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

TAK-279 - a highly selected oral TYK2 inhibitor - being pursued in psoriasis, inflammatory bowel disease and lupus

https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/

4/5

User Avatar

Charlie Lees

3y ago

I'll write more about what these other developments mean in Atomic IBD next week

https://charlielees.substack.com/

5/5